Longevity Clinic Standards 2026: Governance and Minimum…

Reviewed August 27, 2026. The main source is a 2024 narrative review that proposes a healthy-longevity clinic framework. It explicitly says there is no universally accepted model and that further research is needed.¹ It is not an official standard, guideline, or accreditation. Several authors list an affiliation with Longaevus Technologies LTD. The safeguards below are a WLC editorial framework for due diligence.

Quick answer

A serious longevity clinic is not defined by the number of tests in its package. Before comparing biomarkers, look for eight minimum safeguards:

Scope: the clinic states what it can and cannot diagnose or treat.
Medical accountability: licensed professionals and escalation duties are named.
Evidence labels: established care, emerging evidence, and exploratory services are separated.
Result pathway: each abnormal finding has confirmation, referral, and follow-up rules.
Records: source reports, methods, and decisions are exportable.
Data governance: collection, sharing, retention, AI use, and deletion are explained.
Safety: adverse events, false positives, complaints, and no-treatment decisions are recorded.
Conflicts: ownership, referral payments, product sales, and research interests are disclosed.

If a clinic fails a safety-critical gate, more technology does not compensate for it. WLC therefore no longer assigns an overall numeric “standards score.” This is not a certification scheme.

This page covers facility-level governance. For the contents of one patient’s assessment, see what a longevity health assessment should include.

The minimum evidence pack

Ask for documents, not assurances.

Evidence	What a buyer should be able to verify
Clinical governance chart	Medical director, treating professionals, jurisdictions, and escalation cover
Scope statement	Services offered, exclusions, emergency limits, and referral boundaries
Sample report	Methods, uncertainty, evidence labels, priorities, and responsible reviewer
Abnormal-result policy	Urgency categories, contact windows, confirmation, and handoff
Consent and price documents	Optional tests, total likely costs, cancellation, and financial interests
Data notice	Vendors, AI processing, research use, retention, export, and deletion
Safety policy	Adverse-event recording, complaints, and independent escalation
Treatment criteria	Indications, contraindications, alternatives, stop rules, and reasons not to treat

Public logos, testimonials, and a medical advisory board are not substitutes for these materials.

1. Scope and medical accountability

The clinic should state whether it provides screening, diagnosis, treatment, coaching, research, or a combination. Those activities have different duties. A wellness coach should not be presented as the clinician responsible for an abnormal scan, and an algorithm should not become the unnamed decision-maker.

Verify:

the name, qualification, licence, and jurisdiction of each clinical role;
who signs the final report;
who is available for urgent results;
how the clinic coordinates with primary care and specialists;
what happens when a service falls outside the team’s competence;
whether telehealth advice is legally provided where the patient is located.

A good scope statement also lists what the clinic does not offer. Restraint is a quality signal when evidence or expertise is insufficient.

2. Evidence labels should appear at the point of sale

The proposed healthy-longevity framework combines established risk assessment with wearables, biomarkers, AI, and emerging interventions.¹ That breadth makes evidence labels essential. A clinic should not place a routine blood-pressure check, a biological-age assay, and an unapproved regenerative intervention in the same undifferentiated menu.

A practical label system is:

Label	Meaning	Minimum communication
Established	Supported for a defined clinical use	Indication, expected benefit, harms, alternatives
Emerging	Promising but limited for this use	Evidence limits, uncertainty, cost, and follow-up
Exploratory	Research-oriented or not clinically validated for the claim	No implied diagnosis or guaranteed treatment benefit
Not offered	Risk, evidence, or scope is unacceptable	Reason for declining and appropriate alternatives

The label must apply to the specific use, not the technology in general. A validated laboratory method can still be used to support an unvalidated longevity claim.

3. Core care before frontier testing

A clinic should first capture medical history, medications, family history, symptoms, blood pressure, conventional cardiometabolic risk, kidney and liver context, relevant screening history, sleep, function, physical activity, and social factors. The exact assessment depends on the person and jurisdiction.

For example, the U.S. Preventive Services Task Force recommends adult blood-pressure screening and confirmation outside the clinic before starting treatment.² This illustrates a general safeguard: the pathway after a possible abnormality matters as much as the initial measurement.

Frontier testing should answer an additional, explicit question. If the same decision follows from established information, the clinic should explain why the extra test is worth its false-positive risk, cost, and data exposure.

4. AI diagnostics need a named use and human owner

“AI-powered” is not a clinical description. Ask the clinic to identify:

the product and version;
its intended use and patient population;
whether it is a medical device for that use and its regulatory status;
the input data and important exclusions;
known performance limits and false-positive pathway;
the licensed professional who reviews the result;
how model changes are recorded over time.

The FDA maintains a list of AI-enabled medical devices authorized for marketing in the United States.³ The list can help verify a named device, but inclusion does not validate every longevity claim, every patient group, or an off-label workflow. The FDA also describes AI within software as a medical device as technology that may make predictions, recommendations, or decisions, which makes lifecycle management and change control important.⁴

Do not accept a vendor badge or generic claim as proof. Request the device name and the exact role it plays.

5. Biomarkers are not patient outcomes

The FDA-NIH BEST resource defines a biomarker as an indicator of a biological process or response, not a direct measure of how a person feels, functions, or survives.⁵ A biomarker may still be useful, but the report should state:

what it measures and by which method;
the clinical or exploratory question;
important pre-analytic factors;
uncertainty and comparability over time;
what decision could change;
what evidence does not yet support.

Biological-age tests require particular restraint. A lower algorithmic age does not establish rejuvenation, disease prevention, or longer survival. Changing an assay or model version can also break the trend.

6. Regenerative, peptide, and exosome offers require caveat-first handling

The U.S. FDA warns consumers about illegally marketed regenerative medicine products and states that approval for one use does not mean approval for other uses.⁶ The ISSCR patient guide similarly recommends checking evidence, oversight, risks, and regulatory status before treatment.⁷

Before any high-uncertainty intervention, require:

the exact product, active ingredient, source, and manufacturer;
the approved status and proposed indication in the relevant jurisdiction;
evidence for that specific indication, not a neighbouring condition;
alternatives, including no treatment;
contraindications, adverse-event process, and stop rules;
total cost and financial relationships;
long-term follow-up and emergency contact.

“Personalized” does not lower the evidence or consent standard.

7. Records, interoperability, and data governance

Patients should be able to leave with their data and clinical context. At minimum, request laboratory source reports, imaging reports and files, clinician notes, medication changes, device names, assay versions, and the action plan.

HL7 FHIR is a standard for exchanging electronic health information.⁸ A clinic’s ability to export structured data can reduce friction, but using FHIR does not by itself prove clinical quality, privacy, or completeness. Verify the actual export, not the acronym.

The data notice should identify:

which vendors receive health or wearable data;
whether data train or evaluate AI systems;
whether de-identified data are sold, licensed, or used for research;
retention and deletion rules;
cross-border transfers;
the patient’s export and correction rights;
what changes when membership ends.

8. Safety, conflicts, and no-treatment decisions

Serious clinics measure what went wrong. Ask how they record adverse effects, false positives, unnecessary referrals, complaints, and missed escalation. Ask who reviews patterns across patients.

Financial disclosure should include clinic ownership, in-house pharmacies or laboratories, referral fees, supplement margins, device partnerships, and research sponsorship. A conflict does not automatically invalidate a service, but hiding it prevents informed evaluation.

Finally, request examples of reasons the clinic would not order a test or sell a treatment. A service that has no exclusion criteria is a sales funnel, not a clinical standard.

Critical red flags

An overall score or badge is presented as accreditation without an accrediting body.
The medical director is named, but responsibility after abnormal results is not.
Established and experimental services share the same claims language.
AI products or assay versions are not disclosed.
Every test result leads to something the clinic sells.
Records are available only inside a proprietary dashboard.
The consent form omits conflicts, alternatives, or total likely costs.
There is no adverse-event or complaint process.
The clinic cannot explain when it would recommend no testing or no treatment.
Testimonials replace outcome and safety definitions.

Buyer checklist

What activities are medical care, wellness, or research?
Who is licensed to make each decision in my location?
Which services are established, emerging, or exploratory for my use?
Who owns urgent and abnormal results?
Can I see a de-identified report and consent form before paying?
Which companies receive my data, and for what purpose?
Can I export source records and device or assay details?
How are harms, false positives, and complaints tracked?
What financial interests influence referrals or products?
What findings would make the clinic decline a test or treatment?

Bottom line

There is no universally accepted longevity-clinic standard in 2026. Buyers should be sceptical of any self-created score presented as certification.

The most defensible minimum is governance that can be inspected: named accountability, precise evidence labels, explicit result pathways, portable records, data transparency, active safety monitoring, conflict disclosure, and a demonstrated willingness not to sell a service.

Sources

Mironov S, et al. A Framework for an Effective Healthy Longevity Clinic. Aging and Disease. 2024. DOI: 10.14336/ad.2024.0328-1. ↩ ↩²
U.S. Preventive Services Task Force. Hypertension in Adults: Screening. Accessed August 27, 2026. ↩
U.S. Food and Drug Administration. Artificial Intelligence-Enabled Medical Devices. Content current June 16, 2026. Accessed August 27, 2026. ↩
U.S. Food and Drug Administration. Artificial Intelligence in Software as a Medical Device. Accessed August 27, 2026. ↩
FDA-NIH Biomarker Working Group. BEST Resource. Glossary last revised January 16, 2025. Accessed August 27, 2026. ↩
U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Accessed August 27, 2026. ↩
International Society for Stem Cell Research. A Closer Look at Stem Cells: Patient Handbook. Accessed August 27, 2026. ↩
HL7 International. FHIR Overview, Release 5. Accessed August 27, 2026. ↩